MBX Stock Analysis: MBX Biosciences, Common | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 2.751m USD | 12M Return: 381.4% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 41.9M
Warnings
Tailwinds
Seasonality 1.8 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
MBX Biosciences, Inc. (NASDAQ: MBX) is a U.S.-based, clinical-stage biopharmaceutical company founded in 2018 and headquartered in Carmel, Indiana, that is developing precision peptide therapies for endocrine and metabolic disorders. As a clinical-stage biotech, the company is pre-commercial and relies on capital markets and R&D progress rather than product revenue to fund its pipeline.
The companys lead candidate, Canvuparatide (MBX 2109), is a parathyroid hormone peptide prodrug currently in Phase 3 development for chronic hypoparathyroidism. Its second program, Imapextide (MBX 1416), is a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist in Phase 2 for post-bariatric hypoglycemia, a chronic complication of bariatric surgery, representing a differentiated approach within the broader GLP-1 therapeutic class that has drawn significant industry attention.
MBX is also advancing MBX 4291, an obesity product candidate currently in investigational new drug (IND)-enabling studies for obesity and related co-morbidities. The company went public in September 2024 and is classified within the Health Care sector (Biotechnology sub-industry) with a mid-cap valuation.
- Phase 3 Canvuparatide data readout in chronic hypoparathyroidism
- Obesity candidate MBX 4291 enters competitive GLP-1 landscape
- Cash runway and dilution risk as R&D spending accelerates
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.18 > 0.02 and ΔFCF/TA 9.73 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.17 > 3% & CFO -77.5m > Net Income -86.6m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 30.79 > 1.5 & < 3 |
| Outstanding Shares: last quarter (46.6m) vs 12m ago 39.40% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.09%; Δ -0.09% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.96 (Total Current Assets 448.5m - Total Current Liabilities 14.6m) / Total Assets 452.7m |
| B: -0.55 (Retained Earnings -248.0m / Total Assets 452.7m) |
| C: -0.25 (EBIT TTM -86.6m / Avg Total Assets 349.3m) |
| D: 29.29 (Book Value of Equity 437.8m / Total Liabilities 14.9m) |
| Altman-Z'' = 33.59 = AAA |
As of July 08, 2026, the stock is trading at USD 62.00 with a total of 756,531 shares traded. Over the past week, the price has changed by +15.13%, over one month by +113.79%, over three months by +105.37% and over the past year by +381.37%.
Current recommended Stop Loss: 57.70 (which is 6.9% or 1.3 ATR below the current price).
MBX Biosciences, Common has received a consensus analysts rating of 4.60. Therefore, it is recommended to buy MBX.
- StrongBuy: 3
- Buy: 2
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 69.1 | 11.4% |
P/B = 6.077
Revenue TTM = 0.0 USD
EBIT TTM = -86.6m USD
EBITDA TTM = -86.4m USD
Long Term Debt = 377k USD (estimated: total debt 555k - short term 178k)
Short Term Debt = 178k USD (from shortTermDebt, last quarter)
Debt = 555k USD (from shortLongTermDebtTotal, last quarter) (leases 555k already included)
Net Debt = -439.4m USD (calculated: Debt 555k - CCE 440.0m)
Enterprise Value = 2.31b USD (2.75b + Debt 555k - CCE 440.0m)
Interest Coverage Ratio = unknown (Ebit TTM -86.6m / Interest Expense TTM 0.0)
EV/FCF = -28.96x (Enterprise Value 2.31b / FCF TTM -79.8m)
FCF Yield = -3.45% (FCF TTM -79.8m / Enterprise Value 2.31b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 324k) / Revenue TTM)
Tobins Q-Ratio = 5.11 (Enterprise Value 2.31b / Total Assets 452.7m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 555k)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -68.4m (EBIT -86.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 30.79 (Total Current Assets 448.5m / Total Current Liabilities 14.6m)
Debt / Equity = 0.00 (Debt 555k / totalStockholderEquity, last quarter 437.8m)
Debt / EBITDA = 5.09 (negative EBITDA) (Net Debt -439.4m / EBITDA -86.4m)
Debt / FCF = 5.51 (negative FCF - burning cash) (Net Debt -439.4m / FCF TTM -79.8m)
Total Stockholder Equity = 353.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -24.79% (Net Income -86.6m / Total Assets 452.7m)
RoE = -24.50% (Net Income TTM -86.6m / Total Stockholder Equity 353.4m)
RoCE = -24.48% (EBIT -86.6m / Capital Employed (Equity 353.4m + L.T.Debt 377k))
RoIC = -15.61% (negative operating profit) (NOPAT -68.4m / Invested Capital 438.3m)
WACC = 12.83% (E(2.75b)/V(2.75b) * Re(12.83%) + D(555k)/V(2.75b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 12.83% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 95.45 | Cagr: 453.5%
[DCF] Fair Price = unknown (Cash Flow -79.8m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.02 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: N/A | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.60 | Chg30d=+0.00% | Revisions=+67% | Analysts=8
EPS next Quarter (2026-09-30): EPS=-0.74 | Chg30d=+0.00% | Revisions=+38% | Analysts=8
EPS current Year (2026-12-31): EPS=-2.75 | Chg30d=+0.00% | Revisions=+42% | GrowthEPS=-15.5% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-3.94 | Chg30d=+0.20% | Revisions=+50% | GrowthEPS=-43.2% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: +65% (up=20, down=3)